Invitation to presentation of Recipharm’s interim report for the third quarter of 2014 on 7 November

Recipharm will publish its interim report for January-September 2014 on 7 November at 07:45 CET. 

The company invites investors, analysts and media to a conference call with a web presentation (in English) on 7 November at 10:00 CET, where CEO Thomas Eldered and CFO Björn Westberg will present and comment on the interim report and answer questions.

The report will be available on Recipharm’s website www.recipharm.com from 07:45 CET the same day.

To participate in the teleconference, please dial:

From Sweden, tel: +46 8 506 443 86
From Denmark, tel: +45 32 71 42 62
From Finland, tel: +358 9 8171 0375
From Norway, tel: +47 21 06 61 13
From the UK, tel: +44 20 7153 9154
From Germany, tel: +49 69 2017 44 210
From France, tel: +33 1 70 70 95 02
From Spain, tel: +34 914 142 009
From Switzerland, tel: +41 44 580 65 22
From the US, tel:+1 877 423 0830

Pin code for participants: 942621#

To access the presentation during the conference, please use the following link:
http://event.onlineseminarsolutions.com/r.htm?e=884203&s=1&k=BD5F68B778595AA605A9D778C06DA2DA

To access the presentation afterwards, please use the following link:
http://event.onlineseminarsolutions.com/r.htm?e=884203&s=1&k=BD5F68B778595AA605A9D778C06DA2DA

For more information, please contact:
Björn Westberg, CFO

Tel: +46 8 602 46 20; e-mail: bjorn.westberg@recipharm.com

For questions about participation in the event, please contact:
Linda Holmström, Brand & Communications Manager

Tel: +46 70 873 40 95; e-mail: linda.holmstrom@recipharm.com

Tags:

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 6.0 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com

Subscribe

Documents & Links